Evinacumab
Evinacumab is a monoclonal antibody designed for the treatment of dyslipidemia.
Brand name Evkeeza, is
A monoclonal antibody medication for the treatment of homozygous familial hypercholesterolemia (HoFH).
Evinacumab binds to the angiopoietin-like protein 3 (ANGPTL3).
Angiopoietin-like 3 (ANGPTL3)
Evinacumab binds to the angiopoietin-like protein 3 (ANGPTL3).
ANGPTL3 slows the function of enzymes that break down fats in the body.
Evinacumab blocks ANGPTL3, allowing faster break down of fats that lead to high cholesterol.
Routes of administration subcutaneously (SC) or intravenously (IV).
In a controlled, double-blind study evaluated the safety and efficacy of evinacumab administered subcutaneously (SC) or intravenously (IV) in subjects with elevated TGs and/or LDL-C: dose-responsive reductions in TG with median % changes from baseline of -1.0% to -75.0%.
Evinacumab’s effectiveness and safety were evaluated in a double-blind, randomized, placebo-controlled, 24-week trial enrolling 65 participants with homozygous familial hypercholesterolemia (HoFH).
At week 24, participants receiving evinacumab had an average 47% decrease in LDL-C while participants on the placebo had an average 2% increase.
It is intended for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (HoFH).
Common side effects include nasopharyngitis, influenza-like illness, dizziness, rhinorrhea and nausea.
Serious allergic reactions have occurred.